Trastuzumab Deruxtecan Demonstrates Efficacy For Mcrc In Destiny-Crc01

Trastuzumab Deruxtecan Demonstrates Efficacy for mCRC in DESTINY-CRC01

Targeted Oncology

HER2+ mBC: Study Design and Results of DESTINY-Breast01

32 month follow-up of MOUNTAINEER: tucatinib and trastuzumab in HER2+ mCRC

Trastuzumab-Deruxtecan: A Game-Changer in HER2-Positive Cancers │ Pharmacology

Pharmacology Insights

Trastuzumab Deruxtecan (ENHERTU) Superior Efficacy in Breast Cancer SABCS 2024 - Aditya Bardia, MD

Remarkable data: trastuzumab deruxtecan for HER2+ BC

Trastuzumab deruxtecan gives strong anti-tumour activity in multiple tumour types

Tucatinib and trastuzumab in the treatment paradigm of HER2-positive mCRC

DESTINY-CRC02: antibody-drug conjugates in colorectal cancer

Updates from DESTINY-Gastric 01

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated w...

MOUNTAINEER: impact of genomic alterations on tucatinib plus trastuzumab activity in mCRC

Trastuzumab Deruxtecan: Effects in Multiple Cancer Types

Updated analysis from MOUNTAINEER: tucatinib and trastuzumab for HER2-positive mCRC

DESTINY-Gastric02: 2L T-DXd in HER2+ gastric cancers

Trastuzumab Deruxtecan in HER2+ Breast Cancer

Targeted Oncology

How will the PARADIGM trial change the mCRC treatment landscape?

Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJM

Dr. Peters Discusses Ongoing Research With Trastuzumab Deruxtecan in NSCLC

Managing side effects in prolonged treatment with trastuzumab deruxtecan